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Ciprofloxacin is a potent antibacterial drug that is widely used in human clinical
applications. As a consequence of its extensive use, resistance has emerged in almost
all clinically relevant bacterial species. A mean to combat the observed ciprofloxacin
resistance is by reversing it via co-administration of a potentiating compound, also
known as a helper drug. Here, we report on the current advances in identifying
ciprofloxacin helper drugs, and put them into perspective of our own findings. We
searched for potential helper drug targets in Escherichia coli strains with different
levels of ciprofloxacin resistance using transcriptomics i.e., RNAseq and by deletion of
genes associated with hyper-susceptibility to ciprofloxacin. Differential gene expression
analysis of the highly ciprofloxacin resistant uropathogenic E. coli strain, ST131 UR40,
treated with a clinically relevant concentration of ciprofloxacin (2 µg/mL), showed that
the transcriptome was unaffected. Conversely, genetic screening of 23 single gene
deletions in the high-level ciprofloxacin resistant laboratory derived E. coli strain, LM693,
led to a significant decrease in the minimal inhibitory concentration for several genes,
including genes encoding the AcrAB-TolC efflux pump, SOS-response proteins and the
global regulator Fis. In addition, deletion of acrA, tolC, recA, or recC rendered two E. coli
strains with intermediate susceptibility to ciprofloxacin fully susceptible according to the
CLSI recommended breakpoint. Our results corroborate the AcrAB-TolC efflux pump
and the SOS response proteins, RecA and RecC, as potential targets for ciprofloxacin
helper drugs in treatment of human bacterial infections caused by E. coli strains with
intermediate sensitivity to ciprofloxacin.
Keywords: antibiotic resistance, ciprofloxacin, helper drugs, RNA-Seq, transcriptomics
INTRODUCTION
Fluoroquinolones are some of the most prescribed antibacterial drugs in the world, commonly
used for the treatment of urinary tract infections and sinusitis (Emmerson and Jones, 2003; Linder
et al., 2005; Mitscher, 2005), but this has not always been the case. For the first two decades after
the discovery of nalidixic acid in 1962, and its introduction into the clinic in 1964, the quinolones
Abbreviations: MIC, minimal inhibitory concentration; ST, sequence type.
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were only used to treat uncomplicated urinary tract infections.
This changed with the release of the second generation
quinolones, including ciprofloxacin, which showed significant
activity outside the urinary tract and against a broad spectrum of
both Gram-negative and Gram-positive bacteria. Ciprofloxacin
acts by binding to its targets, DNA gyrase and topoisomerase
IV, inhibiting the native ability of these two enzymes to
re-ligate double stranded DNA breaks, in turn leading to
fragmentation of the chromosome. Due to its mechanism of
action it is sometimes referred to as topoisomerase poison
(Aldred et al., 2014). Inevitably, considering its extensive use
and misuse, resistance toward ciprofloxacin has increased in
almost all clinically relevant bacteria (Werner et al., 2011;
Dalhoff, 2012). One method to overcome antibacterial resistance
is by combinatorial treatment with a potentiating compound,
also known as a helper drug. A helper drug is by definition
non-antibacterial when administered alone, but it enhances the
activity of the antibiotic when used in concert. The potentiating
effect of a helper drug can be achieved by either direct inhibition
of the resistance mechanism or by targeting endogenous cellular
components and pathways like, cell membranes, eﬄux pumps
and cellular repair systems. A classic example of targeting the
resistance mechanism is the combination of amoxicillin and the
β-lactamase inhibitor clavulanic acid (White et al., 2004). High-
level ciprofloxacin resistance is primarily associated with multiple
target site mutations in gyrA and parC, encoding subunits of the
DNA gyrase and topoisomerase IV, respectively (Aldred et al.,
2014). Since 1998 three different plasmid-mediated ciprofloxacin
resistance mechanisms have been identified; (i) target protection
(Qnr proteins), (ii) eﬄux pumps (QepA and OqxAB) and (iii)
drug modification (AAC(6′)-Ib-cr acetyltransferase) (Rodríguez-
Martínez et al., 2016).
Potential Ciprofloxacin Helper Drug
Targets
Studies of the endogenous cellular mechanisms involved
in ciprofloxacin susceptibility and resistance evolution have
revealed more than two dozen gene deletions that lead to
increased ciprofloxacin susceptibility in wild-type Escherichia
coli (Cirz et al., 2005; Tamae et al., 2008; Liu et al., 2010;
Yamada et al., 2010). Thus, suggesting the gene products as
potential ciprofloxacin helper drug targets. Recently, Tran et al.
identified 23 single gene deletions that increased the ciprofloxacin
susceptibility of a laboratory derived resistant E. coli strain.
The most significant increase in ciprofloxacin susceptibility
was observed for the deletion of SOS-response genes directly
involved in DNA damage repair, and the genes encoding the
AcrAB-TolC eﬄux pump (Tran et al., 2016). Recacha et al.
recently showed that deletion of recA rendered a laboratory
derived E. coli strain with intermediate sensitivity to ciprofloxacin
clinically susceptible in vitro. In addition, the in vivo efficacy of
ciprofloxacin against the same strain was significantly increased
in a peritoneal sepsis murine model (Recacha et al., 2017).
Thus, the current evidence suggests that targeting the repair of
ciprofloxacin induced DNA damage or the eﬄux pump AcrAB-
TolC are the most promising strategies for ciprofloxacin helper
drugs. Here, we used a combined transcriptomic and genetic
approach in an attempt to both identify novel helper drug targets,
as well as further assess the potential of known helper drug targets
in laboratory derived E. coli strains with different levels and
mechanisms of ciprofloxacin resistance.
MATERIALS AND METHODS
Bacterial Strains and Plasmids
Strains LM693 and LM862 were obtained from Diarmaid
Hughes from Uppsala University. LM693 is isogenic to the
commonly used laboratory strain, MG1655, besides two gyrA
mutations, S83L and D87N, and one parC mutation, S80I.
LM862 is also isogenic to MG1655, but with one gyrA
S83L mutation and one parC S80I mutation. ST131 UR40
has two gyrA mutations, S83L and D87, and two parC
mutations, S80I and E84V, and carries aac-6′-Ib-cr on a plasmid
(Cerquetti et al., 2010). The aac-6′-Ib-cr carrying plasmid
pRNK1 (was constructed as follows: aac-6′-Ib-cr gene was
amplified by PCR from ST131 UR40, using the following
primers: GATCGGATCCATGAGCAACGCAAAAACAAAGTT
AGGC and CATCGAATTCTTAGGCATCACTGCGTGTTCGC,
and cloned into pMW119 (Nippon Gene, Toyama, Japan)
using BamHI and EcoRI. The qnrS-carrying plasmid pRNK9
was constructed as follows: qnrS was amplified by PCR
from the clinical E. coli isolate EC38 using the following
primers: GATCGGATCCATGGAAACCTACAATCATACATAT
CGGC and GATCAAGCTTTTAGTCAGGATAAACAACAAT
ACCCAGTGC, and cloned into pMG25 using BamHI and
HindIII (M. Mikkelsen and K. Gerdes, unpublished). pRNK1
(4796 bp) and pRNK9 (4723 bp) was then introduced in LM862
by electroporation. Strain EC38 was isolated from a patient with
a urinary tract infection at Hvidovre Hospital, Denmark.
Genetic Screening and MIC Tests
For the genetic screen, P1 phage lysates were prepared from the
relevant Keio collection strains (Baba et al., 2006) and used for
transduction into LM693 and LM862. All the transduced strains
were verified by PCR. The ciprofloxacin MICs for LM693 and
derived strains were determined using E-tests (0.002–32 µg/ml,
BioMerieux) and according to the manufacturer’s guidelines.
The MICs for LM862 and derived strains were determined
by broth micro-dilution using cation adjusted Mueller Hinton
broth II with 1 mM and 10 µM IPTG for pRNK1 and
pRNK9, respectively. The two different IPTG concentrations
were used to obtain a ciprofloxacin MIC for LM862/pRNK1 and
LM862/pRNK9 of 2 µg/mL i.e., within the CLSI intermediate
susceptible range. The reference E. coli strain ATCC 25922 was
used as standard in all MIC tests and the susceptibility was
evaluated according to CLSI recommended breakpoints.
Checkerboard Assay
All wells in a micro-titter plate were filled with 100 µl cation
adjusted Mueller Hinton broth II (200 µL in the negative control
wells). Copper phtalocyanine-3,4′,4′′,4′′′-tetrasulfonic acid, was
added to the first row, followed by serial dilution along the
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abscissa, leading to a start concentration of 100 µM. Hereafter
ciprofloxacin was serial diluted along the ordinate, giving a
start concentration of 2 and 64 µg/ml for LM862 and LM693,
respectively. Hundred microliter diluted culture with an OD600
of 0.001 was then inoculated in each well and the plates were
incubated at 37◦C for 24 h.
RNA-Sequencing
Ciprofloxacin was added to a culture of ST131 UR40, which
had been growing exponentially for more than six generations,
to a final concentration of 2 µg/ml. Samples for RNA isolation
were taken at 0 min (prior to ciprofloxacin addition) and 30
and 90 min after ciprofloxacin addition, which has previously
been shown to be long enough to induce fragmentation of the
E. coli chromosome (Charbon et al., 2014). Total RNA was
isolated using a Thermo Scientific GeneJET RNA isolation kit.
Dnase treated with TURBO DNA-free kit from Ambion. rRNA
was depleted using an Illumina Ribo-zero rRNA removal kit,
followed by RNA-Seq library prep using an Illumina TruSeq
Stranded mRNA Library Prep Kit. Sequencing was performed on
an Illumina Miseq with a Miseq reagent kit v3. (75 bp paired-
end) from Illumina. Data analysis was performed in Rockhopper
ver.2.03 (McClure et al., 2013). E. coli NA114 (ST131) (accession
number: NC_017644) was used as reference genome (Avasthi
et al., 2011). The percentage of successfully aligned reads varied
from 91 to 88% of the total read count. The sequencing data files
and the Rockhopper results from the differential gene expression
analysis are available from the Gene Expression Omnibus (GEO:
GSE89507).
RESULTS
Identification of Helper Drug Targets by
Genetic Screening
As mentioned in the introduction several single gene deletions
are known to increase the ciprofloxacin susceptibility of E. coli.
To further assess the helper drug target potential of these
genes, 23 single gene deletions were introduced into the high-
level ciprofloxacin resistant E. coli strain LM693 (MIC of 24–
32 µg/ml) (Marcusson et al., 2009) and tested for hyper-
susceptibility toward ciprofloxacin (Table 1). LM693 is isogenic
to the commonly used laboratory strain MG1655 besides two
GyrA mutations; S83L and D87, and one ParC mutation; S80I.
Even though nine of the mutant strains showed a three to
four fold reduction in the MIC, none of them were found
to be susceptible according to the CLSI MIC breakpoint for
ciprofloxacin (≤1 µg/mL). Our results therefore indicate that
none of the tested gene-knockouts identify valid helper drug
targets in high-level ciprofloxacin resistant E. coli strains.
However, they could potentially be used as helper drug targets
in bacteria with intermediate susceptibility to ciprofloxacin. To
create two strains with intermediate ciprofloxacin susceptibility,
we constructed the plasmids pRNK1 and pRNK9 carrying
the ciprofloxacin resistance determinants aac-6′-Ib-cr and
qnrS, respectively. AAC-6′-Ib-cr inactivates ciprofloxacin by
N-acetylation of the amino nitrogen of its piperazinyl substituent
(Robicsek et al., 2006), while QnrS acts as a DNA mimic, binding
to and protecting the gyrase from the action of ciprofloxacin
(Rodríguez-Martínez et al., 2016). Introduction of pRNK1 and
pRNK9 into strain LM862, which carries GyrA S83L and ParC
S80I mutations, increased the MIC from 1 to 2 µg/ml, i.e.,
into the CLSI intermediate susceptible MIC range. We then
evaluated the ability of seven of the most promising gene
deletions described above to reduce the ciprofloxacin MIC of
LM862/pRNK1 and LM862/pRNK9. Four of the gene deletions
(acrA, tolC, recA, and recC) rendered both strains susceptible to
ciprofloxacin (Table 2). To assess whether inhibition of RecA
was an amenable strategy for potentiation of ciprofloxacin,
synergy between ciprofloxacin and a RecA inhibitor, copper
phtalocyanine-3,4′,4′′,4′′′-tetrasulfonic acid (Alam et al., 2016),
was tested by a checkerboard assay. However, we did not observe
a reduction in the ciprofloxacin MICs for either LM693 or
LM862.
Identification of Helper Drug Targets by
RNA Sequencing
The E. coli clonal group ST131 has become the predominant
E. coli lineage isolated from human extra-intestinal infections and
is currently regarded a global problem in hospitals and clinical
practices (Nicolas-Chanoine et al., 2014). Two independent
studies have shown that more than 90% of ESBL-producing
TABLE 1 | MIC values for the single gene deletions in LM693.
Strain/single deletions MIC (µg/ml)
LM693 24–32
tolC 1.5
acrA, acrB and fis 2
recC, xseA, xseB, uvrD, and recA 4
ruvC and dksA 6
recG and hlpA 8
pgm, ybgF and ybgC 12
deoR, ydcS, yciT and ybjQ 16
ygcO and nlpC 24
rimK 24–32
TABLE 2 | MIC values for the single gene deletions in LM862/pRNK1 and
LM862/pRNK9.
Strain MIC (µg/ml)
LM862 1 1
LM862/Empty vectors 1 1
pRNK1 pRNK9
LM862 2 2
tolC 0.25 0.5
acrA 0.25 0.5
recA 0.5 0.5
recC 0.5 0.5
uvrD 2 1
xseA 1 1
fis 2 4
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ST131 isolates are also resistant to ciprofloxacin (Brisse et al.,
2012; López-Cerero et al., 2014). Strain ST131 UR40 is resistant
to high levels of ciprofloxacin due to GyrA mutations S83L and
D87, and ParC mutations S80I and E84V (Cerquetti et al., 2010).
Here we used RNA-Seq to map the transcriptomic changes during
treatment of ST131 UR40 with a clinically relevant concentration
of ciprofloxacin, 2 µg/ml, which is approximately equal to the
maximum serum concentration following oral administration of
500 mg ciprofloxacin according to the FDA. The rationale behind
this was to identify potential helper drug target genes that were
upregulated upon ciprofloxacin exposure and thereby potentially
involved in ciprofloxacin resistance. In contrast to the genetic
screen, the RNA-Seq analysis would also reveal targets encoded
by essential genes and non-coding RNA. The transcriptomic
analysis did not show any non-ribosomal transcripts to be
significantly upregulated in the presence of ciprofloxacin, i.e.,
with a false discovery rate of <1% and more than two-fold
expression change.
DISCUSSION
By utilizing a combination of “direct genetic screening” and
differential gene expression analysis, we have attempted to
identify potential genes suitable as targets for ciprofloxacin
potentiating compounds. We did not find any genes to be
significantly upregulated by ciprofloxacin, indicating that the
transcriptome of ST131 UR40 was relatively unaffected by
treatment with a sub-inhibitory and yet clinically relevant
concentration of ciprofloxacin. The lack of an upregulation of the
SOS response genes in the transcriptomic analysis suggests that
the ciprofloxacin exposure did not cause sufficient DNA damage
to induce a SOS response; hence it was not necessary for ST131
UR40 to upregulate any specific genes to cope with the presence
of ciprofloxacin at a sub-inhibitory concentration.
The screening of selected mutant strains revealed a number
of genes, which when deleted, lowered the MIC for ciprofloxacin
significantly in LM693. These findings are in accordance with
genes reported to contribute to high-level ciprofloxacin resistance
by Tran et al. (2016). Treatment of bacteria with ciprofloxacin
generates double stranded breaks in the DNA of the organism
(Drlica et al., 2008), which in turn activates the SOS response.
Seven of the tested gene deletions; recA, recC, recG, uvrD,
xseAB, and ruvC, which all significantly reduced the MIC
of LM693, are part of the SOS response and involved in
DNA damage repair (Chase and Richardson, 1974; Kuzminov,
1993; Michel, 2005). Thus, deletion of any of these seven
genes likely lowers the ability of the bacteria to cope with
ciprofloxacin induced DNA damage. Deletion of genes encoding
the AcrAB-TolC eﬄux pump, or the global regulator Fis
(Factor for inversion stimulation) showed the largest decreases
in MIC values for LM693. The Fis protein has been shown
to repress the gyrA and gyrB promoters, thereby reducing the
expression of the DNA gyrase (Schneider et al., 1999). Thus,
deletion of fis likely increases DNA gyrase expression and
the number of ciprofloxacin targets. As ciprofloxacin works
as a topoisomerase poison, an increase in ciprofloxacin bound
DNA gyrase could potentially lead to an increase in double
stranded breaks, explaining the decrease in MIC for the fis
deletion strain. The fis deletion did not have the same effect
on the intermediate susceptible strains LM862/pRNK1 and
LM862/pRNK9, which may be explained by the relatively higher
affinity of ciprofloxacin for its target in LM862, compared
to that of LM693. Thus, the increase in expression of the
DNA gyrase might lead to an increase in ciprofloxacin-gyrase
complexes, but if the ciprofloxacin induced DNA damage is
already at a level, where the DNA repair mechanisms cannot
keep up, the fis deletion does not have a dramatic effect on the
MIC.
Individual deletions of acrA, acrB, or tolC genes encoding the
AcrAB-TolC eﬄux pump had a large effect on the ciprofloxacin
susceptibility of both LM693 and LM862 strains. This was
not surprising as overexpression of the AcrAB-TolC eﬄux
system has been connected to ciprofloxacin resistance numerous
times (Mazzariol et al., 2000). The deletion of acrA or tolC
in the LM862 strains lowered the MIC beneath the CLSI
susceptible breakpoint indicating that AcrAB-TolC eﬄux system
is a potential target for ciprofloxacin potentiating compounds
in intermediate susceptible E. coli. A number of AcrAB-TolC
inhibitors have been identified (Chevalier et al., 2004; Bohnert
et al., 2013; Aparna et al., 2014; Opperman et al., 2014; Yilmaz
et al., 2015), two of which have been shown to decrease the MIC
of ciprofloxacin in susceptible E. coli strains (Opperman et al.,
2014; Yilmaz et al., 2015), but none of them are used in clinical
practice so far.
Inhibition of RecA and thereby of the SOS response has been
proposed as a strategy to fight antibiotic resistance numerous
times (Blázquez et al., 2012; Culyba et al., 2015; Alam et al., 2016).
Our finding, that deletion of recA render intermediate susceptible
strains of E. coli fully susceptible to ciprofloxacin is in accordance
with recent observations by Recacha et al. (2017). Overall, this
indicates that RecA could be a potential ciprofloxacin helper drug
target.
Even though AcrAB-TolC or RecA deficiency rendered
LM862/pRNK1 and LM862/pRNK9 susceptible to ciprofloxacin,
the respective MICs were only two to four-folds lower than the
susceptible MIC breakpoint. It therefore seems reasonable to
assume that a given inhibitor should completely block the activity
of either RecA or AcrAB-TolC in order for it to be an efficient
helper drug. This hypothesis is backed by the failure of lowering
the ciprofloxacin MIC of LM862 and LM693 with the RecA
inhibitor phtalocyanine-3,4′,4′′,4′′′-tetrasulfonic acid.
CONCLUSION
The findings of this study and the evidence given in the
literature, indicates that reversal of ciprofloxacin resistance in
high-level resistant E. coli strains by the use of helper drugs
does not appear to be plausible. Conversely, targeting RecA,
RecC or the AcrAB-TolC eﬄux pump is a likely feasible strategy
for reversing ciprofloxacin resistance in E. coli strains with
intermediate susceptibility to ciprofloxacin. However, it should
be noted that there is a discrepancy between the MIC breakpoint
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for ciprofloxacin susceptibility proposed by the CLSI (≤1µg/mL)
and the EUCAST (≤0.25 µg/mL). Therefore, further in vivo
studies are needed to asses if targeting either RecA, RecC, or
AcrAB-TolC leads to a significant increase in the efficacy of
ciprofloxacin against an intermediate susceptible E. coli strain.
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